Transcept won't let Retrophin increase stake in company
This article was originally published in Scrip
Executive Summary
Point Richmond, California-based Transcept Pharmaceuticals turned down Retrophin's request to increase its stake in the company from 4.9% ownership to up to 15%, marking another rejected attempt by Retrophin to grab more shares of Transcept.